( 母液浓度为 40 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们客服联系。| 中文名称: | MYCMI-6 促销 一键复制产品信息 | ||||
|---|---|---|---|---|---|
| 英文名称: | MYCMI-6 | ||||
| 别名: | NSC354961 | ||||
| CAS No: | 681282-09-7 | 分子式: | C20H19N7O | 分子量: | 373.41 |
| CAS No: | 681282-09-7 | ||||
| 分子式: | C20H19N7O | ||||
| 分子量: | 373.41 | ||||
基本信息
|
产品编号:M10787 |
|||||
|
产品名称:MYCMI-6 |
|||||
|
CAS: |
681282-09-7 |
储存条件 |
粉末 |
-20℃ |
四年 |
|
|
|
||||
|
分子式: |
溶于液体 |
-80℃ |
六个月 |
||
|
分子量 |
373.41 |
-20℃ |
一个月 |
||
|
化学名: |
|
||||
|
Solubility (25°C) |
体外 |
DMSO |
|
||
|
Ethanol |
|
||||
|
Water |
|
||||
|
体内(现配现用) |
|
|
|||
|
<1mg/ml表示微溶或不溶。 |
|||||
|
普西唐提供的所有化合物浓度为内部测试所得,实际溶液度可能与公布值有所偏差,属于正常的批间细微差异现象。 |
|||||
|
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;⼀旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |
|||||
制备储备液
|
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
|
1mM |
2.6780mL |
13.3901mL |
26.7802mL |
|
5mM |
0.5356mL |
2.6780mL |
5.3560mL |
生物活性
|
产品描述 |
一种有效的选择性内源性 MYC:MAX 蛋白相互作用抑制剂。 |
||
|
靶点/IC50 |
c-Myc |
Apoptosis |
|
|
体外研究 |
MYCMI-6 (NSC354961) (6.25μM; 48 hours) selectively suppresses MYC-driven tumor cell growth with high efficacy.MYCMI-6 significantly inhibits growth of Burkitt’s lymphoma cells (Mutu,Daudi and ST486) - another classical example of a MYC-driven tumor, having translocations of MYC to one of the immunoglobulin loci - in a dose-dependent manner with an average GI50 of 0.5μM.Treatment of MCF7 cells with the MYCMI-6 for 24 hours significantly decreased MYC:MAX isPLA signals to 7%. Titration showed an IC50 for inhibition of MYC:MAX of less than 1.5μM for MYCMI-6 by isPLA. MYCMI-6 inhibits the MYC:MAX heterodimer formation with an IC50 of 3.8μM.MYCMI-6 efficiently inhibits anchorage-independent growth of MYCN-amplified neuroblastoma cells with GI50 values of <0.4μM. |
||
|
Cell Line: |
MYCN-amplified neuroblastoma cells (IMR-32, Kelly and SK-N-DZ), MYCN-non-amplified neuroblastoma cells (SK-N-F1, SK-N-AS and SK-N-RA) |
||
|
Concentration: |
6.25μM |
||
|
Incubation Time: |
48 hours |
||
|
Result: |
Result: Reduced growth of the MYCN-amplified cell lines significantly stronger than the MYCN-nonamplified cell lines. |
||
|
体内研究 |
MYCMI-6 (20mg/kg; i.p.; daily for 1-2 weeks) induces massive apoptosis and reduces tumor cell proliferation, tumor microvasculature density and MYC:MAX interaction in a MYC-dependent xenograft tumor model. |
||
|
Animal Model: |
6-8 weeks old athymic nude mice (bearing MYCN-amplified SK-N-DZ neuroblastoma cells) |
||
|
Dosage: |
20 mg/kg body weight |
||
|
Administration: |
I.p.; daily for 1-2 weeks |
||
|
Result: |
A dramatic increase in the extension of apoptotic areas in the tumors and a significant increase in non-proliferative areas as determined by Ki67 staining in tumors. |
||
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液,使用的计算公式为:
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为:C1V1 = C2V2 ( 输入 输出 )
母液,添加 300 μLPEG300
混匀澄清,再加 50μLTween80, 混匀澄清,再加 600μLSaline/PBS/ddH2O
混匀澄清方案所需的各种助溶剂如: DMSO , PEG300 / PEG400 , Tween 80 , SBE-β-CD , 玉米油 等, 均可点击跳转或在网站搜索购买。
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
.png)
